Gaetano Santulli, MD
Disclosures: The commentator has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-2922.
Santulli G. In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet. Ann Intern Med. 2020;172:JC6. doi: https://doi.org/10.7326/ACPJ202001210-006
Download citation file:
Published: Ann Intern Med. 2020;172(2):JC6.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use